Vaginitis Therapeutics Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends

Spread the love

Overview and Scope
Vaginitis therapeutics refers to the use of the drugs such as antifungal agents, antibiotics and hormonal medications for treating infection of vagina. These medications or drugs are effectively useful in relieving the symptoms such as itching, discharge, and pain.

Sizing and Forecast
The vaginitis therapeutics market size has grown rapidly in recent years. It will grow from $3.74 billion in 2023 to $4.12 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to high incidence of vaginal infections, women’s health awareness, change in lifestyles and hygiene practices, antibiotic resistance concerns, pharmaceutical research and development..

The vaginitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.03 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to rising emphasis on personalized medicine, increased healthcare access, growing aging population, focus on non-antibiotic therapies, awareness and education initiatives .. Major trends in the forecast period include combination therapies for resistant cases, regulatory advances and guidelines, integration of digital health tools, global collaboration for research, development of non-drug therapies..

To access more details regarding this report, visit the link:

Segmentation & Regional Insights
The vaginitis therapeutics market covered in this report is segmented –

1) By Drug Type: Nitroimidazole Compound, Lincosamide Antibiotics, Triazoles, Imidazoles
2) By Route Of Administration: Oral, Cutaneous, Vaginal
3) By Indication Type: Bacterial Vaginosis, Trichomoniasis, Vulvovaginal Candidiasis, Other Types
3) By End Users: Hospitals, Ambulatory Surgical Centers, Specialized Gynecology Centers, Clinics

North America was the largest region in the global vaginitis therapeutics market in 2023. The regions covered in the vaginitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

Major Driver Impacting Market Growth
The increasing prevalence of sexually transmitted diseases (STDs) is expected to propel the growth of the vaginitis therapeutics market going forward. Sexually transmitted diseases (STDs) are infections spread through sexual contact between infected and uninfected individuals. STDs cause vaginitis leading to vaginal inflammation and pain associated with vaginitis. Vaginitis therapeutics help relieve the symptoms of vaginitis caused by STDs among women leading to high usage of vaginitis drugs. For instance, in April 2023, according to the Center for Disease Control and Prevention, a US-based national public health agency, the number of sexually transmitted diseases (STDs) in the USA increased between 2020 and 2021, reaching more than 2.5 million. Further, the syphilis cases in the US increased by 32% from 133,954 in 2020 to 176,713 in 2021. Therefore, the increasing prevalence of STDs will fuel the vaginitis therapeutics market growth.

Key Industry Players
Major companies operating in the vaginitis therapeutics market report are Pfizer Inc., Merck & Co Inc., Novartis AG, Bayer AG, Lupin Pharmaceuticals Inc., Symbiomix Therapeutics Inc., Mission Pharmacal Company, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Lumavita AG, Abbott Laboratories Ltd., GlaxoSmithKline plc, Sanofi SA, Bristol-Myers-Squibb Co, Eli Lilly and Co, TherapeuticsMD Inc., Scynexis Inc., Sebela Pharmaceuticals Inc., Daré Bioscience Inc., Hologic Inc., Mylan N.V., Viamet Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Cidara Therapeutics Inc., Imprimis Pharmaceuticals Inc., Innovus Pharmaceuticals Inc., Evofem Biosciences Inc., Mycovia Pharmaceuticals, Perrigo Company plc, Mithra Pharmaceuticals, Ferring Pharmaceuticals, AstraZeneca plc, Biocon Limited, Pacira Pharmaceuticals Inc., The Medicines Company

The vaginitis therapeutics market report table of contents includes:

1. Executive Summary
2. Vaginitis Therapeutics Market Characteristics
3. Vaginitis Therapeutics Market Trends And Strategies
4. Vaginitis Therapeutics Market – Macro Economic Scenario
5. Global Vaginitis Therapeutics Market Size and Growth
31. Global Vaginitis Therapeutics Market Competitive Benchmarking
32. Global Vaginitis Therapeutics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Vaginitis Therapeutics Market
34. Vaginitis Therapeutics Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
Healthcare Blog:
Global Market Model:

Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →